Boston、MAにおける膠腫の臨床試験
Bostonとその周辺地域（約30マイル以内）の拠点で、膠腫に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
MCT for the Harvard/UCSF ROBIN Center
被験者募集中
- Brigham and Women's Hospital, Boston
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
被験者募集中第1/2相
- Dana-Farber Cancer Institute, Boston
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
被験者募集中第2相
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
被験者募集中第1/2相
- Dana Farber Cancer Institute., Boston
Targeted Pediatric High-Grade Glioma Therapy
被験者募集中観察研究
- Dana-Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
被験者募集中第2相
- Susan Chi, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
被験者募集中第3相
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
被験者募集中第1/2相
- Research Site, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
CARv3-TEAM-E T Cells in Glioblastoma
被験者募集中第1相
- Massachusetts General Hospital Cancer Center, Boston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
被験者募集中早期第1相健康なボランティア歓迎
- Dana-Farber Cancer Institute, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
被験者募集中第2相
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
被験者募集中第1/2相
- Dana Farber Cancer Institute, Boston
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
被験者募集中早期第1相
- Dana-Farber Cancer Institute, Boston
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
被験者募集中第1相
- Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston
CUE-102 in Recurrent Glioblastoma
被験者募集中第1相
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
NeuroPathways Intervention for Brain Tumor Patients
被験者募集中
- Massachusetts General Hospital Cancer Center, Boston
ASCENT Intervention for Brain Tumor Patients
被験者募集中
- Massachusetts General Hospital Cancer Center, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
被験者募集中観察研究
- Massachusetts General Hospital, Boston
他の都市における膠腫の試験
- New York City, NY25件の研究
- Houston, TX23件の研究
- Washington, DC19件の研究
- Philadelphia, PA16件の研究
- Columbus, OH15件の研究
- Miami, FL15件の研究
- San Francisco, CA14件の研究
- Chicago, IL13件の研究
- Durham, NC12件の研究
- Seattle, WA11件の研究
- Los Angeles, CA10件の研究
- St. Louis, MO10件の研究
Bostonにおける他の研究
- 乳がん111件の研究
- 非小細胞肺癌90件の研究
- がん（全種類）86件の研究
- 大腸癌63件の研究
- 転移性癌63件の研究
- 肺がん62件の研究
- 卵巣がん61件の研究
- 前立腺がん59件の研究
- うつ病52件の研究
- 子宮内膜がん50件の研究
- 心不全44件の研究
- 急性骨髄性白血病44件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。